Pregnancy is well recognized as a critical period in a woman’s life course when physiologic changes intended to support the growing fetus can have adverse sequelae for long-term cardiovascular health. Adverse pregnancy outcomes are rising in prevalence, complicate nearly 1 in 5 pregnancies in the US, and include hypertensive disorders of pregnancy, gestational diabetes, preterm birth, and having a small-for-gestational-age infant.
Ample observational data demonstrate that these adverse pregnancy outcomes are associated with increased maternal risk of cardiovascular disease (CVD) in the short and long term. As a result, pregnancy is commonly referred to as a stress test, which provides a window to future cardiovascular health for women.
This knowledge has led to growing calls by national and international professional societies to recognize pregnancy and the postpartum period as opportunistic moments for CVD risk assessment and cardiovascular health counseling. This recognition of the importance of pregnancy in a person’s overall health has also coincided with growing interest in the potential utility of circulating biomarkers to improve risk assessment in nonpregnant populations.
JAMA Cardiology published a clinical update in Cardiology on 01 Apr 2026.
The item focuses on Assessment for Long-Term Cardiovascular Disease Risk in Pregnancy.
Review the original article for the full source wording and details.